Insulin intensification strategies in type 2 diabetes: When one injection is no longer sufficient

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 5, 2009, Pages 14-18

  Garber, A J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED;

EID: 70350318773     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01139.x     Document Type: Review

References (15)

1. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?. Eur J Clin Invest 2000, 30:3-11. (Suppl. 2):
2. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999, 354:617-621. DECODE Study Group
3. Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med 2006, 23:743-749.
4. Malone JK, Kerr LF, Campaigne BN. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004, 26:2034-2044. Lispro Mixture-Glargine Study Group
5. Malone JK, Bai S, Campaigne BN. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005, 22:374-381.
6. Kazda C, Hülstrunk H, Helsberg K. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006, 20:145-152.
7. Christiansen JS, Vaz JA, Metelko Z. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003, 5:446-454.
8. Raskin P, Allen E, Hollander P. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265. INITIATE Study Group
9. Kann PH, Wascher T, Zackova V. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006, 114:527-532.
10. Garber AJ, Wahlen J, Wahl T. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006, 8:58-66.
11. Lankisch MR, Ferlinz KC, Leahy JL. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185. Orals Plus Apidra and LANTUS (OPAL) Study Group
12. Liebl A, Prager R, Binz K. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009, 11:45-52. PREFER Study Group
13. Ligthelm RJ, Mouritzen U, Lynggaard H. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:511-519.
14. Hirao K, Arai K, Yamauchi M. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008, 79:171-176. Japan Diabetes Clinical Data Management Study Group
15. Rosenstock J, Ahmann AJ, Colon G. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-25.